Corbus Pharmaceuticals (CRBP) announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States ...

Abstract Title: Briquilimab, an Anti-Human CD117 Antibody, Treats Low-Calcemic Vitamin D3 Analog MC903-Induced Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117 Poster Number: 690 ...

And finally, in the fourth quarter of 2024, the company announced positive results from a 28-day Phase 1b clinical ... This presentation highlighted data showing that cohorts receiving VK2735 ...

Initiation of Phase 3 Studies for Subcutaneous VK2735 ... in vivo data from this program at the American Diabetes Association's (ADA's) Annual Scientific Sessions. The company's presentation ...

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

In the second quarter of 2025, the business intends to start Phase 3 studies for their subcutaneous obesity therapy, VK2735 ... Driven by manufacturing and clinical trial expenditures, full ...

announced piflufolastat F 18 data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place February 13-15, 2025, in San Francisco ...

In the dynamic environment of biotechnology trials, the significance of Clinical Data Management systems (CDMs) cannot be overstated. As we navigate the complexities of these trials and the ...